Literature DB >> 32251654

Quantitative Analysis of Anterior Chamber Inflammation Using the Novel CASIA2 Optical Coherence Tomography.

Mingzhi Lu1, Xiaoran Wang1, Lei Lei1, Yang Deng1, Tinglong Yang2, Ye Dai1, Yonghao Li1, Xiaoliang Gan1, Yixin Hu1, Hui Chen1, Meng Li1, Lishi Su1, Jin Yuan1, Wei Chi3.   

Abstract

PURPOSE: We evaluated the clinical utility of a novel anterior segment optical coherence tomography (AS-OCT) device, CASIA2, to evaluate parameters indicative of anterior chamber (AC) inflammation severity in uveitis, including AC cell number, flare, and keratic precipitates (KPs).
DESIGN: Prospective evaluation of a diagnostic device.
METHODS: Uveitis eyes were classified into active and inactive groups. The number of hyper-reflective dots representing AC cells and optical density ratio (aqueous-to-air relative intensity [ARI] index) for flare qualification were calculated from AS-OCT images. Additionally, a program was designed to quantify the posterior corneal surface smoothness (PCSS) of each image for KPs evaluation. The maximum (MAX), minimum (MIN), and average (AVG) PCSS values were calculated from 128 images per eye and compared among active uveitis, inactive uveitis and control eyes. Correlations between SUN grade and both hyper-reflective dot number and ARI index were evaluated. Receiver operating characteristic (ROC) curves were constructed to test the values of these indicators for uveitis diagnosis.
RESULTS: AC hyper-reflective dot count, ARI index, PCSS-MAX and PCSS-AVG were all significantly higher in the active uveitis group than the inactive and control groups. Hyper-reflective dot count and ARI index were associated with SUN cell and flare grade. According to ROC curve analysis, PCSS-MAX was the best indicator for diagnosis of uveitis involving the anterior segment, so as the hyper-reflective dot number to distinguish active from inactive AC inflammation.
CONCLUSIONS: Quantification of AC cell number, flare and KPs using the CASIA2 device is a promising strategy for objective assessment of AC inflammation.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32251654     DOI: 10.1016/j.ajo.2020.03.032

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Quantification of Anterior Chamber Cells in Children With Uveitis Using Anterior Segment Optical Coherence Tomography.

Authors:  Edmund Tsui; Judy L Chen; Nicholas J Jackson; Omar Leyva; Haroon Rasheed; Elmira Baghdasaryan; Simon S M Fung; Deborah K McCurdy; Srinivas R Sadda; Gary N Holland
Journal:  Am J Ophthalmol       Date:  2022-05-21       Impact factor: 5.488

2.  Grading Anterior Chamber Inflammation with Anterior Segment Optical Coherence Tomography: An Overview.

Authors:  Morgan Maring; Steven S Saraf; Marian Blazes; Sumit Sharma; Sunil Srivastava; Kathryn L Pepple; Cecilia S Lee
Journal:  Ocul Immunol Inflamm       Date:  2022-02-17       Impact factor: 3.728

3.  Subtle changes of the crystalline lens after cycloplegia: a retrospective study.

Authors:  Cheng Dai; Meng Liu; Xiaodong Lv; Binzhong Li
Journal:  BMC Ophthalmol       Date:  2021-03-06       Impact factor: 2.209

4.  Lens Biometry in Congenital Lens Deformities: A Swept-Source Anterior Segment OCT Analysis.

Authors:  Ze-Xu Chen; Wan-Nan Jia; Yong-Xiang Jiang
Journal:  Front Med (Lausanne)       Date:  2021-12-20

5.  Novel Findings of Retinal and Choroidal Features Utilizing Optical Coherence Tomography Angiography Analysis in Patients With Autoimmune Posterior Uveitis.

Authors:  Junhui Shen; Jinfeng Kong; Si Chen; Xin Liu; Yan Teng; Hailan Wu; Lijuan Wang; Manman Wu; Zhaoan Su; Lei Feng
Journal:  Front Med (Lausanne)       Date:  2022-01-11

6.  Quantification of Anterior Chamber Particles Using Anterior Segment Optical Coherence Tomography in Angle-Closure Glaucoma Patients after Laser Iridotomy.

Authors:  Naoya Yoshihara; Hiroto Terasaki; Hideki Shiihara; Ryoh Funatsu; Takehiro Yamashita; Taiji Sakamoto
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.